Announced
Completed
Financials
Tags
United States
cancer medicines
discovering and developing medicines
therapeutics
Pharmaceuticals
Acquisition
Domestic
Minority
Private
Private Equity
Venture Capital
Completed
Friendly
Single Bidder
Synopsis
Surveyor Capital, an investment firm, led a $54m Series C round in OnKure Therapeutics, a precision oncology company, with participation from Deep Track Capital, Acorn Bioventures, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, BlackRock, and other undisclosed investors. “We are delighted to be working with our new and existing investors to achieve our vision of developing the next generation of tumor-agnostic, oncology precision medicines.Our team of drug discovery veterans are actively exploring a pipeline of novel oncogene-targeted programs designed to achieve optimal tolerability and efficacy. We look forward to filing our second IND in 2023 and advancing OKI-219 into clinical development early next year,” Tony Piscopio, OnKure Co-Founder, President and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.